MELT-300, a sublingual tablet containing midazolam and ketamine, demonstrated statistically superior sedation compared to sublingual midazolam and placebo in cataract surgery patients.
Melt Pharmaceuticals' MELT-300 demonstrated statistical superiority over sublingual midazolam and placebo in Phase III trial for cataract surgery sedation.
MELT-300, a non-IV, non-opioid sublingual tablet, demonstrated positive topline efficacy in a Phase 3 trial for procedural sedation during cataract surgery.
MELT-300, a sublingual tablet combining midazolam and ketamine, demonstrated statistically superior procedural sedation compared to sublingual midazolam and placebo in cataract surgery patients.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.